Barnett, AH; Millar, HL; Loze, J.-, Y; L'Italien, GJ; van Baardewijk, M; Knapp, M; (2009) UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study). European archives of psychiatry and clinical neuroscience, 259 (4). pp. 239-247. ISSN 0940-1334 DOI: https://doi.org/10.1007/s00406-008-0863-2 Full text not available from this repository.

Calvert, NW; Burch, SP; Fu, AZ; Reeves, P; Thompson, TR; (2006) The cost-effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder. Journal of managed care pharmacy, 12 (4). pp. 322-30. ISSN 1083-4087 https://researchonline.lshtm.ac.uk/id/eprint/10378 Full text not available from this repository.

Lynch, J; Morrison, J; Graves, N; Meddis, D; Drummond, MF; Hellewell, JSE; (2001) The health economic implications of treatment with quetiapine: an audit of long-term treatment for patients with chronic schizophrenia. European psychiatry, 16 (5). pp. 307-12. ISSN 0924-9338 https://researchonline.lshtm.ac.uk/id/eprint/17053 Full text not available from this repository.

Sedrakyan, A; Shih, C; (2007) Improving depiction of benefits and harms - Analyses of studies of well-known therapeutics and review of high-impact medical journals. Medical care, 45 (10). S23-S28. ISSN 0025-7079 DOI: https://doi.org/10.1097/MLR.0b013e3180642f69 Full text not available from this repository.